Karl Qin, M.B.A.

Mr. Qin has over 28 years of management experience at leading biopharma companies and top medical institutions. Mr. Qin has negotiated and closed over 30 commercial transactions with the global healthcare organizations including Pfizer, Eli Lilly, BMS, Myriad Genetics, Millennium, Bausch Lomb and Innovent.

Prior to joining D2M as Chief Business Officer, he was CBO and COO at MediBoston Inc., a venture backed company focused on ADC therapeutics. Mr. Qin also served in senior management positions at several biopharma companies including Genzyme/Sanofi and CDS. Mr. Qin started his career with MD Anderson Cancer Center. As Director of Technology Commercialization, he managed MD Anderson’s venture start- ups and technology licensing.

Mr. Qin hold an MBA from Rice University; M.S. in Cellular Biology from University of Massachusetts, Amherst, and B.S. in Virology from Wuhan University.